Standard Family Office’s Boston Scientific BSX Stock Holding History

Standard Family Office’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-160	Closed	-$6K	–	65
2022 Q3	$6K	Buy	+160	New	+$6.42K	﹤0.01%	286
2021 Q3	–	Sell	-60	Closed	-$3K	–	128
2021 Q2	$3K	Hold	60	–	–	﹤0.01%	292
2021 Q1	$2K	Hold	60	–	–	﹤0.01%	396
2020 Q4	$2K	Buy	+60	New	+$2.16K	﹤0.01%	391

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Standard Family Office's BSX Position: Q4 2022 in Review

Standard Family Office sold out of Boston Scientific (BSX) in Q4 2022, closing a stake of 160 shares — an estimated $6K sold.

Standard Family Office first reported a position in BSX in Q4 2020 and held it in 4 quarters. The position peaked at $6K in Q3 2022. 928 funds tracked by Wall St. Rank hold BSX as of Q4 2022.

Standard Family Office reported no remaining Boston Scientific position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 160 Boston Scientific shares in Q4 2022, an estimated $6K.
Standard Family Office first reported a position in Boston Scientific in Q4 2020 and held it in 4 quarters.
Standard Family Office's Boston Scientific position peaked at $6K in Q3 2022.
928 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.